Showing 1131-1140 of 9359 results for "".
- Merz Signs Licensing Agreement with Brickell Biotech for Development of a Novel Retinoid Therapyhttps://practicaldermatology.com/news/20140702-merz_signs_licensing_agreement_with_brickell_biotech_for_development_of_a_novel_retinoid_therapy/2459182/Merz North America, Inc. signed an agreement with Brickell Biotech, Inc. granting Merz an exclusive North American license with certain additional international rights to develop and commercialize, a completely novel retinoid compound for the treatment of skin conditions responsive to retinoid agen…
- The Skin Type Solutions® Franchise System Launched by Leslie Baumann, MDhttps://practicaldermatology.com/news/20140625-the_skin_type_solutionsfranchise_system_launched_by_leslie_baumann_md/2459189/The Skin Type Solutions® Franchise model, just introduced by dermatologist Leslie Baumann, MD, is intended to allow every dermatologist to be the primary source of skincare guidance before a patient makes a purchase, and make the proper skincare regimens available right there at the office. The S…
- FDA Approves Sivextro to Treat Skin Infections in Adultshttps://practicaldermatology.com/news/20140624-fda_approves_sivextro_to_treat_skin_infections_in_adults/2459192/The FDA approved Sivextro (tedizolid phosphate), a new antibacterial drug, to treat adults with skin infections. Sivextro, which is marketed by Cubist Pharmaceuticals, is approved to treat patients with acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacter…
- Sente, Inc. Awarded European Patent for Active Ingredient in Proprietary Dermal Repair Creamhttps://practicaldermatology.com/news/20140619-sente_inc_awarded_european_patent_for_active_ingredient_in_proprietary_dermal_repair_cream/2459199/Sente has been granted the European Patent for use of a low molecular weight heparan sulfate (HS) for cosmetic products. HS is the most biologically active glycoprotein that is present in all layers of human skin and is the scientific base to Sente Inc's proprietary Dermal Repair Cream. Michael Yo…
- FDA to Require Warnings on Sunlamp Productshttps://practicaldermatology.com/news/20140530-fda_to_require_warnings_on_sunlamp_products/2459227/The FDA issued a final order reclassifying sunlamp products and ultraviolet (UV) lamps intended for use in sunlamp products from low-risk (class I) to moderate-risk (class II) devices. The order also requires that sunlamp products carry a visible black-box warning on the device that explicitly stat…
- Provectus Biopharmaceuticals Reaffirms Commitment to Bring PV-10 to Markethttps://practicaldermatology.com/news/20140528-provectus_biopharmaceuticals_reaffirms_commitment_to_bring_pv-10_to_market/2459229/The FDA will not to give PV-10 breakthrough therapy designation for treatment of patients with locally advanced cutaneous melanoma, because the data did not prove substantial over existing therapies. However, Provectus Biopharmaceuticals says it is still committed to bringing the investigational m…
- Actavis Announces Acanya Gel Patent Challenge Settlementhttps://practicaldermatology.com/news/20140512-actavis_announces_acanya_gel_patent_challenge_settlement/2459243/Actavis plc has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to the Actavis generic version of Acanya (clindamycin phosphate and benzoyl peroxide) Gel 1.2%/2.5%. Acanya Gel is a lincosamide antibiotic …
- Novan Therapeutics to Present Data at 2014 Society for Investigative Dermatology Annual Meetinghttps://practicaldermatology.com/news/20140425-novan_therapeutics_to_present_data_at_2014_society_for_investigative_dermatology_annual_meeting/2459255/Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, will present data from the Phase 2 clinical trial in acne vulgaris with its lead product candidate, SB204, at the 2014 Annual Meeting of the Society for Investigative Dermato…
- ALPHAEON Launches New Patient Financing Solutionhttps://practicaldermatology.com/news/20140425-alphaeon_launches_new_patient_financing_solution/2459256/ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings, LLC, launched ALPHAEON CREDIT, which the company describes as a new tool for patients seeking to finance self-pay lifestyle healthcare procedures through board-certified specialty physicians in dermatology, ophthalmology, plastic surg…
- Sun Pharma Acquires Ranbaxy in a $4 billion US Transactionhttps://practicaldermatology.com/news/20140407-sun_pharma_acquires_ranbaxy_in_a_4_billion_us__transaction/2459276/Sun Pharma will obtain 100% of Ranbaxy in an all stock transaction. The collaboration of these two pharmaceutical companies leads to the fifth largest generics company globally. There will be operations in 65 countries as well as 47 manufacturing facilities across 5 continents. Managing Directo…